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Cancer patients with low or absent pre-existing anti-tumour immunity (“cold” tumours)
respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render
these patients susceptible to ICPI, initiation of de novo tumour-targeted immune
responses is required. This involves triggering of inflammatory signalling, innate immune
activation including recruitment and stimulation of dendritic cells (DCs), and ultimately
priming of tumour-specific T cells. The ability of tumour localised therapies to trigger these
pathways and act as in situ tumour vaccines is being increasingly explored, with the
aspiration of developing combination strategies with ICPI that could generate long-lasting
responses. In this effort, it is crucial to consider how therapy-induced changes in the
tumour microenvironment (TME) act both as immune stimulants but also, in some cases,
exacerbate immune resistance mechanisms. Increasingly refined immune monitoring in
pre-clinical studies and analysis of on-treatment biopsies from clinical trials have provided
insight into therapy-induced biomarkers of response, as well as actionable targets for
optimal synergy between localised therapies and ICB. Here, we review studies on the
immunomodulatory effects of novel and experimental localised therapies, as well as the re-
evaluation of established therapies, such as radiotherapy, as immune adjuvants with a
focus on ICPI combinations.
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HIGHLIGHTS
• Immune checkpoint inhibitors have revolutionised cancer therapy, however they remain largely
ineffective in the treatment of poorly immunogenic “cold” tumours.
• Localised therapies can be used to enhance tumour immunogenicity and overcome resistance to
checkpoint blockade, with minimal additive or overlapping side effects.
• Clinical studies to date have yieldedmixed results, from negative studies to results that have already
changed clinical practice.
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• Future directions include novel combinations featuring
alternative checkpoints, co-stimulatory agonists and agents
that target pathways that may enhance antigenicity. Further
considerations include the optimal scheduling of immune-
modulatory agents.
INTRODUCTION
The last decade has seen a revolution in the field of immuno-
oncology (IO), driven most notably by the approval and clinical
implementation of immune checkpoint inhibitor (ICPI) therapy.
In work later recognised in the 2018 Nobel Prize in Physiology or
Medicine, James Allison and Tasuku Honjo separately identified
two pivotal surface receptors that act as negative regulators of the
effector T cell (Teff) response, Cytotoxic T Lymphocyte
Associated Protein-4 (CTLA-4) (1) and Programmed Cell
Death-1 (PD-1) (2), respectively. CTLA-4 is expressed on both
effector and regulatory T cells and competes with the co-
stimulatory receptor CD28 for shared ligands CD80 and CD86
(3), thereby inhibiting co-stimulatory signals essential for
activation. PD-1 is expressed on activated immune cells and
inhibits TCR signalling by binding with its ligands Programmed
Cell Death-Ligand 1 (PD-L1) or PD-L2 (4). The checkpoints are
immune gatekeepers, with receptor-ligand interactions acting to
regulate the effector response to pathogens and maintain
immune tolerance (3).
These pathways are frequently exploited by tumour cells as a
mechanism of immune evasion. Upregulation of PD-L1 on
tumour cells, or production of factors that upregulate
checkpoint expression on immune cells, leads to exhausted and
dysfunctional effector Teff and promotion of regulatory T cells
(Treg) within the tumour microenvironment (TME).
Monoclonal antibody (mAb) therapy targeting immune
checkpoint pathways was shown to be a potent method of
anti-cancer T cell re-invigoration, effectively releasing the
brakes that are imposed on effector function by checkpoint-
mediated immunosuppression. In 2011, the first anti-CTLA-4
mAb Ipilimumab was approved for clinical use, shortly followed
by agents targeting the PD-1/PD-L1 axis (5).
Checkpoint inhibitors targeting CTLA-4, PD-1, and PD-L1
now form part of first or second-line standard-of-care in
melanoma, non-small cell lung cancer (NSCLC), advanced
head and neck squamous cell cancer (HNSCC), renal cancer
and urothelial cancer, among others (targets summarised in
Table 1). The result is a shift in outlook for a subset of
patients with previously untreatable cancers (6), and for some
a chance of long-term cure. In melanoma, for example, ICPI
therapy has seen huge success. The Checkmate 067 trial of dual
checkpoint blockade (CTLA-4/PD-1) in advanced melanoma
showed a response rate of 58%, with a 52% 5-year survival in a
historically poor-prognosis group (7), and patients with a
complete response were shown to have a less than 10% chance
of relapse on discontinuation of treatment in a study by Robert
et al. with a 2-year median follow up (6).
These have undoubtedly been exciting times for the field of
IO, and the potential for durable therapy with non-overlapping
side-effects continues to bolster clinical and academic interest.
Over 3000 clinical trials involving ICPI or other T cell
modulators are currently ongoing worldwide. Furthermore,
evidence for cancer therapy by inhibition of alternative
checkpoints such as T cell and mucin-domain containing-3
(TIM-3), lymphocyte activation gene-3 (LAG-3) and T cell
immunoreceptor with immunoglobulin and ITIM domain
(TIGIT) is emerging (8).
Although ICPI have revolutionised the treatment landscape,
low response rates and resistance still plague effective therapy for
the majority. On average, only around 12% of patients gain benefit
across all tumour types (9), with particularly low response rates in
sites that are seen to be poorly immunogenic such as primary
brain, pancreatic and ovarian cancer, and liver metastases (10, 11).
Even in sites where ICPI therapy is well established, secondary
resistance remains an issue, as seen in the aforementioned
landmark Checkmate-067 trial which reported an 11.5-month
median duration of response in advanced melanoma (7).
The enduring problem of primary and secondary resistance,
combined with a lack of reliable predictive biomarkers of
response, leaves a large proportion of patients at risk of ICPI-
related toxicity without clinical benefit. A significant focus has
therefore been placed on broadening mechanistic understanding
of ICPI resistance, and developing strategies to augment
response. One strategy is the use of locally-delivered, immune-
modulatory therapies in combination with ICPI. These therapies,
which include radiotherapy and treatments delivered by
intratumoural injection such as oncolytic viruses (OV), can
lead to remodelling of the TME to a more favourable
phenotype for effective ICPI therapy.
Although accessibility of treatable lesions remains a limitation
for some localised therapies, they have several advantages over
TABLE 1 | Current checkpoint inhibitors with regulatory approval.
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systemic combinations. They enable targeted manipulation of
the TME, minimising off-target effects and systemic or
overlapping toxicity. In addition, local treatments have been
shown to exert a systemic influence on TME composition and
anti-cancer immunity, even in non-treated tumours. Examples of
such effects include stimulation of immune cell influx, enhanced
immune cell priming and increased expression of checkpoint
targets (such as PD-1 or PD-L1). These characteristics form part
of the metaphorical notion of the immunological “heat” of a
tumour, and are commonly associated with response to ICPI.
Accordingly, they are characteristically absent in “cold”, ICPI-
refractory tumours. Remodelling of the TME using localised
therapies therefore provides potential for global synergy, and
enhanced ICPI-responsiveness (12). This review will outline the
rationale, pre-clinical and clinical evidence behind localised
therapy-ICPI combinations and explore future directions.
Increasing the Immunological Heat
Immune checkpoints form only part of the complex picture of
effective anti-cancer immunity. Huge diversity in mutational
burden, antigen release and presentation, inflammatory
signalling and TME composition all play a critical role in ICPI
efficacy (13). This diversity and resultant dichotomy in ICPI
response is apparent between patients of the same tumour type,
and even within homogenous mouse tumour models (14).
The unifying concept of tumour Immunological “heat” is a
global representation of this multifactorial diversity and represents
the ability of a tumour to elicit effective anti-cancer immunity.
Immunostimulatory “hot” tumours are seen to be more
responsive to immunotherapy. “Hot” characteristics include an
immune-cell rich TME, high in CD8+ Teff cells with a high CD8:
Treg ratio, antigen-presenting cell (APC) and inflammatory M1-
polarised macrophage infiltration, and immune-stimulatory
cytokine production (such as Type I IFN). High tumour
antigen (TAA) availability due to a high tumour mutational
burden (TMB) or microsatellite instability (MSI) has also been
associated with ICPI responsiveness, and checkpoint expression
on activated, antigen-exposed immune cells, along with PD-L1
on tumour cells, provide targets for ICPI therapy (12).
Immunosuppressive “cold” tumours are seen to be less
responsive to immunotherapy. They feature absent or excluded
Teff, with a higher proportion of immunosuppressive Treg and
M2 polarised macrophages. Poor antigen availability, for
example in tumours with a low TMB and excluded APCs,
means immune cell priming is suboptimal. This inhibits an
effective anti-cancer immune response and renders ICPI
therapy ineffective or even detrimental. For example, PD-1
blockade has been shown to drive T cell dysfunction and anti-
PD-1 resistance in the absence of effective priming (15). A non-
reactive gene signature and immunosuppressive cytokine
production [such as IL10 and transforming growth factor b
(TGF-b)] maintain a paucity of immune cells, and the immune-
inhibitory effects of other TME constituents may predominate,
for example cancer-associated fibroblasts (CAFs), hypoxia and
abnormal vasculature (Figure 1) (16).
Although complex, and by no means universal, where a
tumour sits on the axis of immunological heat is known to
play a pivotal role in the response to ICPI therapy. Resistance
mechanisms can remain dominant at the level of the TME even
when circulating antigen-specific T cells are high (17), and local
manipulation of the TME to increase the “heat” and improve
ICPI responsiveness therefore presents a rational therapeutic
strategy. Localised therapy/ICPI combinations involving
radiotherapy or oncolytic virotherapy have gained the most
clinical momentum to date. Further strategies in clinical
development include agonists of immune-stimulatory pathways
such as Stimulatory of Interferon Genes (STING) and Toll-Like
Receptor (TLR) signalling, or physical modification or the TME
using thermal treatments, such as high-intensity focused
ultrasound (HIFU) or photothermaltherapy (18). This review
will outline the effects of these treatments on TME composition
and immunogenicity in “cold” tumours, and explore the
evidence behind their combination with ICPI therapy.
Cellular and Molecular Mechanisms
Underlying Immune Activation
Despite distinct differences in their mechanisms of action, the
localised therapies featured in this review share some
commonality in the basic immune-modulatory pathways
through which they exert their immune effects and enhance
ICPI therapy (summarised in Table 2). Advances in
immunology research have validated radiotherapy-induced
DNA damage as a viral mimic (34), triggering the same
intrinsic anti-viral inflammatory pathways that are naturally
stimulated by OV therapy (35). These protective pathways can
also be targeted downstream by other agents such as TLR or
STING agonists, and form the cellular machinery that enable
recognition and presentation of pathogenic material or cellular
defects - leading to an inflammatory signalling cascade and an
innate and adaptive immune response.
Pattern-recognition receptors (PRRs) expressed on innate
immune cells have evolved to detect microbial pathogenic
molecules collectively known as pathogen-associated molecular
patterns (PAMPs). The cytosolic nucleic acid sensors cyclic
GMP-AMP synthase (cGAS) and retinoic acid inducible gene I
(RIG-I) are not only important for detection of infected cells but
also for immune recognition of cancer cells (36). Changes in the
composition and abundance of cytosolic double-stranded DNA
(dsDNA) and dsRNA induced during tumorigenesis, or by
cellular stress following therapy, are detected by PRRs such as
cGAS and RIG-I respectively, resulting in activation of STING
and mitochondrial antiviral-signalling protein (MAVS). The
resulting complex downstream signalling, including IRF3 and
NFkB-dependent pathways, ultimately leads to expression of
type I interferons (IFNs) and other pro-inflammatory
cytokines (37, 38).
Two decades ago, Polly Matzinger postulated that immune
activation can also occur in the absence of microbial products,
instead being triggered by inflammatory signals released from
stressed or dying cells (39), which are collectively named
damage-associated molecular patterns (DAMPs). DAMPs such
as ATP, HMGB1 and calreticulin are hallmarks of the highly
inflammatory process of immunogenic cell death (ICD), which is
defined as a regulated cell death mechanism capable of inducing
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an adaptive immune response in the host. Release of the
metabolic mediator ATP into the extracellular space triggers
recruitment and activation of DCs via P2Y2 and P2X7 receptors
respectively (40, 41), while secretion of HMGB1 activates DCs
via TLR-4 (42). Translocation of calreticulin to the cell surface
provides an “eat-me” signal to antigen-presenting cells and
results in phagocytosis of the target cell (43). In the context of
cancer, ICD leads to release of tumour-associated antigens
(TAA) and subsequent priming of a cancer-specific
immune response.
FIGURE 1 | Immunologically “cold” tumours are generally unresponsive to ICPI and characterised by low infiltration and/or exclusion of cytotoxic lymphocytes,
including CD8 T cells and NK cells. Further, cold tumours often have high infiltration of immunosuppressive cells including Tregs, CAFs, and M2-polarized
macrophages as well as low expression and presentation of tumour neoantigens preventing priming of de novo immune responses. Immunogenic localised therapies
are designed to convert ‘cold’ tumours to a ‘hot’ by altering the adjuvanticity and antigenicity of the TME. Antigenicity is achieved by augmented expression,
degradation and presentation of tumour neoantigens while adjuvanticity is associated with elevated levels of DAMPs, released from dying tumour cells, cytosolic DNA
accumulation and sensing, and a transcriptional profile geared towards IFN type I signalling. Together, these factors promote recruitment, infiltration and activation of
DCs allowing for increased antigen cross-presentation and priming of tumor-specific CD8 T cells. Triggering of these events by localised therapies creates a
favourable environment for synergy with ICPI. The pool of activated cross-presenting DCs cooperates with anti-CTLA-4 treatment to generate a broadened repertoire
of tumour neoantigen-specific T cells whose effector function can be augmented by anti-PD-1 treatment in their killing of tumour cells locally and systemically. TME,
tumour microenvironment; DAMP, danger-associated molecular pattern; DC, dendritic cell; CAF, cancer-associated fibroblast; ICPI, immune checkpoint inhibitor; NK
cell, natural killer cell.
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Together, therapy-induced inflammatory PAMP and DAMP
signalling generate a favourable environment for activated DCs
to process and cross-present tumour-derived antigens to naïve T
cells, which can prime and sustain a systemic tumour-specific
immune response in synergy with ICPI. Induction of ICD, and
the resultant increase in adjuvanticity of the tumour, is therefore
a key mechanism underlying the efficacy of immunogenic
localised therapies such as OV and radiotherapy.
ONCOLYTIC VIROTHERAPY
Oncolytic viruses (OV) are naturally-occurring or genetically-
modified (GM) viruses that selectively infect and destroy tumour
cells through direct cell lysis and stimulation of an anti-cancer
immune response (44). Many tumour cells are intrinsically
sensitive to viral infection due to common deficiencies in key
anti-viral machinery that enables unhindered viral replication
while normal tissue is spared (45), a characteristic that can be
optimized for safety and selectivity through variant selection or
viral genetic modification.
The immune stimulatory effects of OV are multi-modal. Viral
replication triggers cell lysis and ICD. This releases viral progeny
to continue the lytic cascade in surrounding tumour cells, as well
as TAA for cross-priming of APCs and DAMPs, subsequently
leading to stimulation of a Type 1 IFN-mediated anti-tumour
immune response (46). The cell intrinsic anti-viral apparatus also
plays an integral role in OV-mediated immunity. Viral DNA and
RNA are sensed by PRRs such as cGAS and RIG-I respectively,
triggering an ATP-dependent inflammatory cascade mediated by
STING, leading to JAK/STAT pathway upregulation and pro-
inflammatory cytokine release (47).
The result is a switch to an immune-stimulatory TME, with
influx of activated T cells and APCs, upregulation of MHC and
co-stimulatory markers such as CD40, CD80 and CD86 (48), as
well as enhanced antigen presentation. This leads to the
upregulation of PD-1 and CTLA-4 by T cells, potentiating
immune checkpoint inhibition. This OV-mediated immune-
stmulation also presents a barrier to effective OV monotherapy,
mediating adaptive resistance and leading to exhausted Teff and
Treg influx. Synergy between ICPI and OV herefore has the
potential to work both ways; OV may enhance response to
ICPI, and conversely ICPI may enhance the efficacy of OV.
In 2015, the oncolytic Herpes Simplex Virus (oHSV),
talimogene laherparepvec, became the first OV to gain
regulatory approval for cancer therapy (49), leading to an
acceleration in OV research. Since this milestone, evidence for
the widespread clinical implementation of OV monotherapy has
been limited. The 26% ORR and 23.3-month median OS seen
with T-Vec in advanced melanoma was surpassed by dual
checkpoint blockade, and to date no further OV have gained
FDA approval.
What has become apparent is the potential of OV therapy as
an immune adjuvant in combination with other immune-
modulatory therapies, such as ICPI. In combination, OV
present an appealing prospect. They exhibit anti-cancer activity
and tumour selectivity, are generally well-tolerated with non-
overlapping side-effects, and have the ability to increase
the immunological heat of OV-injected and non-injected
tumours – a phenomenon demonstrated in both pre-clinical
animal models and patients (50).
A further advantage of OV therapy is the application of OV as
viral vectors. The large backbone of some OV, such as oncolytic
Herpes Simplex Virus (oHSV), Adenovirus (oADV) or Vaccinia
Virus (oVV) can be manipulated by insertion of therapeutic
transgenes, thus exploiting selective viral replication for
concentrated delivery of immune-modulatory agents within the
TME. This provides a unique opportunity, not only to
manipulate the TME to enhance ICPI therapy, but to deliver
the ICPI themselves. This is a particular advantage when
considering the delivery of molecules where systemic
administration may be limited by toxicity or pharmacokinetic
considerations. Examples include the anti-CTLA-4 mAb, or
potent immune-stimulators such as agonists of the 4-1BB co-
stimulatory receptor or stimulatory cytokine IL-12.
Several clinical trials of OV/ICPI combinations are currently
ongoing or have recently been completed, backed by pre-clinical
evidence of synergistic effects. This section will focus on the
rationale and evidence behind locally-delivered OV and ICPI
TABLE 2 | Summary of key mechanisms of therapeutic synergy between localised therapy combinations and ICPI.
Therapy-induced mechanisms Immunogenic effects promoting synergy with ICPI References
Nucleic acid sensing Induced IFN type I signalling (19–23)
cGAS/STING activation ! T cell recruitment
RIG-I/MAVS activation ! Augmented CD8 T cell cytotoxicity
! Increased DC cross-priming
DAMP release/exposure
(24–26)ATP Recruitment and activation of DCs
HMGB1 Increased phagocytosis
CALR Production of pro-inflammatory cytokines
Neo-antigen expression and processing Increased peptide pool (27–31)
Increased diversity of TCR repertoire
Generation of tumour specific T cells
MHC class I upregulation Augmented CD8 T cell priming (27)
Enhanced tumour cell killing
Death-receptor upregulation Augmented NK cell and CD8 T cell cytotoxicity (32, 33)
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therapy combinations; strategies featuring systemic OV delivery
are reviewed in detail elsewhere (51).
Localised OV and Checkpoint Blockade
Combinations – Pre-Clinical Studies
Extensive pre-clinical research has evaluated the mechanisms
behind OV remodelling of the TME in “cold” tumours, and the
implications for subsequent checkpoint blockade. Among the
most clinically advanced OV to date are variants of the oHSV
and oADV viral platforms, double-stranded DNA viruses that
are not only highly immune-stimulatory, but have large viral
backbones that provide opportunity for transgene insertion.
Zhang et al. showed that oHSV therapy led to an increase in
tumour-infiltrating CD4 and CD8 T cells and a decrease in Treg
and suppressive TAM in a mouse model of pancreatic
ductal adenocarcinoma (PDAC). PDAC is a notoriously
immune-excluded, “cold” tumour, with a TME comprising
immunosuppressive Treg, tumour associated macrophages
(TAM), immunosuppressive cytokines and physical barriers to
T cell infiltration such as CAFs and a desmoplastic stroma (52).
Transcriptome profiling of immune cells following treatment
showed enrichment of PD-1, LAG-3 and TIM-3 in the CD8 T
cell population, and OX40 and CTLA-4 in the CD4 population
(53). Accordingly, triple combination therapy (OV/PD-1/CTLA-
4) was shown to significantly prolong survival in PDAC tumour-
bearing mice.
HF-10 (Canepaturev, CRev) is a further oHSV1 which
contains natural mutations that enhance selectivity. HF-10
treatment led to an influx of CD8 T cells in a poorly
immunogenic HNSCC model, with infiltration of PD-L1-
expressing macrophages and DCs in both OV-injected and
non-injected tumours. Despite a PD-L1-enriched TME, a
therapeutic effect was seen with single-agent HF-10 treatment;
however, this was significantly enhanced by addition of anti-PD-
L1 therapy. Interestingly, synergy was seen with high-dose, but
not low-dose, anti-PD-L1 therapy highlighting a dose-dependent
factor in the ability of ICPI to overcome either the intrinsic
tumour-mediated immunosuppression or OV-induced
checkpoint upregulation (54).
Saha et al. showed enhanced CD8 T cell infiltration in
an 005-GSC-derived GBM mouse model following treatment
with a third-generation triple-mutated oHSV encoding the
immunostimulatory cytokine IL-12 (G47DV-mIL-12) (55).
Glioblastoma multiforme (GBM) is a highly immunosuppressive
tumour, with low response rates to single and dual checkpoint
blockade and added immuno-therapeutic complexity provided by
the blood-brain barrier and tissue hypoxia (55). In addition to Teff
infiltration, changes were seen in other TME cell compartments,
with a decrease in the proportion of Treg and an increase in the
CD8 T cell/Treg ratio. A shift was seen towards pro-inflammatory
M1-polarised macrophages with an increase in IFNy production,
indicating a more-immunogenic tumour phenotype. Modest
synergy was seen when G47DV-mIL-12 was combined with
single agent ICPI (PD-1 or CTLA-4), however triple therapy
(OV/PD-1/CTLA-4) led to long-term cures and protection from
tumour re-challenge. This treatment effect was dependent on CD4
and CD8 T cells, as well as macrophages, highlighting the complex
relationship between constituents of the TME, and the potential
need for multi-targeted therapy to overcome tumour-
mediated immunosuppression.
Adenovirus is a double-stranded DNA virus which has again
been extensively investigated in the context of OV therapy,
including for GBM. Stereotactic administration of low dose
oADV was shown to upregulate PD-1 expression on tumour-
infiltrating CD8 T cells, highlighting a mechanism of adaptive
resistance. Synergy was seen with anti-PD-1 therapy, with
significantly improved survival in GBM tumour-bearing mice (56).
Evidence of efficacy of an oADV encoding co-stimulatory
ligand CD40-L was shown by Singh et al. in a mouse melanoma
model. Melanoma has been well-established as an immunogenic
“hot” tumour site. Despite this, 50% of patients do not respond to
dual checkpoint blockade. The B16 mouse melanoma model is
highly immunosuppressive, with an immune-excluded TME and
production of immunosuppressive cytokines such as TGF-b.
Remodelling of the TME was seen following treatment, with an
influx of IFNy-producing CD8 T cells, an increase in the CD8:Treg
ratio and upregulation of PD-L1 on tumour tissue. Combination
treatment with anti-PD-L1 enhanced therapy and led to an
increase in CTLA-4-expressing CD8 T cells. Subsequent triple
therapy (OV/PD-L1/CTLA-4) significantly improved response,
leading to regression of OV-injected and non-injected lesions
(including brain metastases). A 45% cure rate was achieved,
with protection from tumour re-challenge (57). Hu et al. also
demonstrated synergy between a modified oADV, this time armed
with immunostimulatory cytokine IL-24, and PD-1 blockade in
B16-melanoma tumour-bearing mice. Treatment increased CD8
T cells, Tregs and CD11b+ myeloid cells, with MHC upregulation
on APCs and production of inflammatory cytokines (58).
Interestingly, although anti-tumour immunity was seen to be
dependent on viral attachment and entry, the oADV did not
successfuly infect and lyse cells and, therefore, lead to PAMP/
DAMP release, and hence did not induce anti-tumour immunity
through these mechanisms. Instead, oADV treatment appeared to
label tumour cells as “non-self”, leading to enhanced MHC-1 and
co-stimulatory CD80 expression, and presentation of “non-self”
viral epitopes on the tumour-cell surface, triggering an anti-cancer
immune response. This highlights the complex mechanisms
surrounding the immune-stimulatory effects of OV (59).
The vaccinia poxvirus, historically used as a vaccine for
smallpox since the late 19th century, is also in clinical
development as an OV. The modified oVV pexastimogene
devacirepvec (JX-594) has yielded disappointing results in
clinical trials to date, most notably with the failure of the phase
3 PHOCUS trial in liver cancer (60). However, it has shown pre-
clinical promise in combination with ICPI therapy. Remodelling
of the TME was demonstrated by Chon et al. following IT JX-594
therapy, with an influx of CD8 T cells and NK cells, upregulation
of inflammatory genes and a switch to an immune-stimulatory
TME in mouse breast and renal cancer models. As with other
studies, combinaton with single-agent ICPI enhanced therapy,
however triple therapy (OV/PD-1/CTLA-4) led to complete,
durable tumour regression (61). Similar trends were seen in
other studies of poorly immunogenic mouse colon and ovarian
cancer models (62, 63).
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An alternative therapeutic strategy is using OV as viral
vectors to deliver ICPI therapy through insertion of transgenes
encoding checkpoint blocking antibodies, an attractive prospect
when considering complex immunomodulatory combinations
and avoidance of systemic ICPI toxicity. Having said that,
encoding ICPI or immune activating ligands within OV may
present some limitations, not least of all the fact that the two
components of therapy are obligatorily expressed within the
same tissue compartment, which may not always be the
optimum means of combination. Kleinpeter et al. showed that
insertion of murine anti-PD-1 into an oVV backbone enhanced
therapeutic effects in a poorly-immunogenic mouse
fibrosarcoma model (64). Therapy led to a higher and more
prolonged intra-tumoural anti-PD-1 concentration than IT
injection of the antibody itself, highlighting the advantage of
viral replication in dose amplification. Blood levels of anti-
CTLA-4 mAb were also shown to be low following IT delivery
of the GM oVV BT001 encoding anti-CTLA-4 and GM-CSF,
while IT levels were sufficient to suppress CTLA-4 receptor
function for days to weeks following injection (65).
Additional pre-clinical evidence was presented by Zuo et al.
Up to 70% complete and durable tumour regression was seen in
mouse tumour models following treatment with an oVV
encoding novel checkpoint TIGIT, which is highly expressed
on natural killer T cells (NKT) and Tregs. Treatment stimulated
a CD8 T cell-mediated anti-tumour response with evidence of
immune memory and protection from re-challenge. High levels
of anti-TIGIT mAb were seen in tumour tissue, but not in blood
from treated mice (66). A TK-gene deleted oVV expressing anti-
PD-1 and an anti-4-1BB co-stimulatory receptor agonist was also
shown to suppress tumour growth in mouse models of liver and
pancreatic cancer (67).
The oHSV platform is also amenable to genetic modification.
Coffin et al. developed the RP oHSV platform, featuring ICP34.5
and ICP47 deletions to attenuate neurovirulence and enhance
antigen presentation and GALV-GP-R and hGM-CSF insertion to
enhance OV-induced ICD. Further modification with insertion of
ICPI or co-stimulatory ligands (CTLA-4, 4-1BB, CD40-L and
OX40-L) was shown to increase therapeutic efficacy in tumour-
bearing mice (68). Enhanced therapy, this time with an anti-PD-1
armed oADV was also demonstrated by Zhang et al. The un-
modified oADV was shown to increase TME immune infiltration
and promote PD-L1 upregulation but failed to prolong survival.
Genetic modification with the addition of the extracellular
domains of PD-1 and CD137L (4-1BBL) led to a 70% long-term
cure rate in a sub-cutaneous hepatocellular carcinoma (HCC)
model (69). A further modified oADV, LOAd703, also encodes 4-
1BBL, along with TMZ-CD40-L, and has shown pre-clinical
activity in PDAC mouse models (70).
Other OV in clinical development include polioviruses,
Newcastle disease virus (NDV), reovirus and maraba virus.
Clinical trials involving both reovirus and NDV in
combination with ICPI therapy are ongoing, with pre-clinical
evidence of synergy (3, 49, 71, 72); however, these are focused on
systemic delivery, and as such are reviewed elsewhere. The non-
neurovirulent rhinovirus:poliovirus chimera PVSRIPO was
shown to synergise with anti-PD-1 and anti-PD-L1 therapy in
mouse triple-negative breast cancer (TNBC) models (73) and is
currently the subject of early-phase clinical trials. Maraba virus is
a member of the Rhabdovirus family of RNA viruses, and was
shown to increase Treg and PD-L1 expression when given prior
to tumour resection in mouse breast cancer models. Post-
operative addition of dual ICPI therapy (CTLA-4/PD-1) was
shown significantly to prolong survival when compared to virus
or ICPI alone (74).
CLINICAL TRANSLATION
Herpes Simplex Virus
Oncolytic viruses based on the Herpes Simplex Virus-1 (oHSV-1)
have gained the most clinical traction to date following the
approval of T-Vec in the treatment of melanoma. In T-Vec, the
HSV backbone has been modified by deletion of ICP34.5 and
ICP47 and insertion of GM-CSF to enhance selectivity and
immune effects. T-vec was shown to induce antigen-specific
local and systemic immunity in phase II studies, with an
increase in CD8 T cell density in injected and non-injected
lesions, increased checkpoint expression (50), and an increase in
melanoma antigen-specific T cells (75).
T-Vec/ICPI combination therapy has to date yielded mixed
results. A phase II trial of IT Tvec and Ipilimumab therapy in
advanced melanoma showed a significant improvement in
response (38% vs 18%) with regression of non-injected lesions
and no additional safety concerns (76). However, a phase III study
evaluating T-Vec in combination with Pembrolizumab was
recently terminated due to futility at interim analysis (77),
despite promising translational data in the phase 1b part of the
the trial (78). The MASTERKEY-232 phase Ib study evaluated
Tvec in combination with Pembrolizumab in recurrent or
metastatic HNSCC. PFS and OS was comparable to documented
results of Pembrolizumab monotherapy, and phase III was not
pursued (79). As is a common IO theme, impressive and durable
responses are seen for a minority. For example, Khaddour et al.
reported a case of complete, durable tumour regression in a patient
with melanoma with brain metastases following T -Vec,
Atezolizumab and Temozolomide therapy (80). This highlights
that there is much still to learn about the biology underpinning
these and future complex combinatorial strategies. Several trials
featuring T-Vec/ICPI combinations are ongoing (Table 3).
The spontaneous oHSV mutant HF-10 has also been
evaluated in clinical trials in combination with ICPI therapy. A
phase II study of HF-10 and Ipilimumab in advanced melanoma
demonstrated an acceptable safety profile with a best overall
response rate (BORR) of 41% and 19-month median PFS (81).
Responding patients had influx of CD4 and CD8 T cells, along
with increased CD4 ICOS expression and PD-L1 upregulation
on monocytes. HF-10 was also evaluated in combination with
Ipilimumab in patients with treatment-refractory acral and
mucosal melanoma with an 11.1% BORR and 55.5% disease
control rate (82).
The RP oHSV platform developed by Coffin et al. (RP1, RP2
and RP3) is undergoing clinical evaluation, with ongoing phase I
and II trials in combination with anti-PD-1 or anti-PD-L1 agents
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in advanced solid tumours (Table 3). An oncolytic HSV-2 virus
was also evaluated in a first-in-human phase 1b study in
combination with anti-PD-1 therapy in metastatic oesophageal
and rectal cancer patients. Remodelling of the TME was
apparent, with CD8 T cell infiltration and increased PD-L1
expression, along with evidence of regression of both injected
and non-injected lesions (52).
Adenovirus
Several oADV are in clinical development and have been tested
in combination with ICPI therapy. ONCOS-102 is an oADV
with a 24bp deletion in the E1A Rb binding site to attenuate
replication in normal tissue, and addition of GM-CSF for
immune augmentation. A two-part phase I study of ONCOS-
102 in combination with concurrent or sequential anti-PD-1
therapy provided evidence of the ability of OV to overcome ICPI
resistance. This trial recruited advanced melanoma patients that
were refractory to prior anti-PD-1 therapy, and reported a 35%
ORR in an early analysis (NCT03003676). A phase I study of
ONCOS-102 in combination with Durvalumab in ovarian and
colorectal cancer with peritoneal metastases showed an increase
in CD8 T cell infiltration and PD-L1 expression following
treatment. Some evidence of clinical activity was seen, but only
1 durable response. Phase II recruitment is ongoing
(NCT02963831). DNX-2401 is a further oADV with E1A
deletion. A phase II dose escalation study of IT DNX-2401 in
TABLE 3 | Summary of ongoing clinical trials evaluating oncolytic virotherapy in combination with immune checkpoint inhibition.





NCT04185311 T-Vec + Ipilimumab + Nivolumab Active, not recruiting. Phase 1. Neo-adjuvant, breast cancer (TNBC, ER
+HER2-)
NCT03842943 T-Vec + Pembrolizumab Recruiting. Phase 2, neo-adjuvant, stage 3 resectable melanoma
NCT04068181 T-Vec + Pembrolizumab Active, not recruiting. Phase 2, metastatic melanoma following progression
on anti-PD1 therapy
NCT03069378 T-Vec + Pembrolizumab Recruiting. Metastatic/locally advanced sarcoma
NCT02509507 T-Vec + Pembrolizumab Recruiting, phase 1b/2. Liver tumours (HCC and liver metastases)
NCT04050436 RP1 + Cemiplimab Recruiting
Phase II
Locally advanced or metastatic cutaneous SCC (CSCC)
NCT03767348 RP1 + Nivolumab Recruiting
Phase 1/2
Advanced and/or refractory solid tumours
NCT04336241 RP2 + Nivolumab Recruiting
Phase 1, advanced solid tumours
NCT04735978 RP3 + Nivolumab Recruiting
Phase 1, advanced solid tumours
NCT04348916 ONCR-177 + Pembrolizumab Recruiting. Phase 1, advanced solid tumours and liver metastases
Adenovirus
NCT04387461 Intravesical CG0070 + Pembrolizumab Recruiting
Phase 2, non-muscle invasive bladder cancer
NCT02636036 Enadenotucirev + Nivolumab Active, not recruiting
Phase 1, metastatic or advanced epithelial tumours
NCT02798406 DNX-2401 + Pembrolizumab Active, not recruiting
Phase 2, glioblastoma and gliosarcoma
NCT04123470 LOAd703 + Atezolizumab Recruiting
Phase 1/2, Metastatic melanoma
NCT02705196 LOAd703 + Atezolizumab + standard of care
(Gemcitabine/nab-Paclitaxel)
Recruiting. Phase 1/2. Pancreatic cancer.
NCT03172819 OBP-301 + Pembrolizumab Active, not recruiting
Phase 1, advanced or metastatic solid tumours
NCT03921021 OBP-301 + Pembrolizumab Recruiting
Phase 2, esophagogastric adenocarcinoma
NCT03003676 ONCOS 102 + Pembrolizumab Active, not recruiting. Phase 1, advanced melanoma after progression on
anti-PD-1 therapy
NCT02963831 ONCOS 102 (intraperitoneal) + Durvalumab Recruiting, phase II
Vaccinia virus
NCT03294083 Pexa-Vec (JX-594) + Cemiplimab Recruiting, phase 1b/2a, metastatic or unresectable RCC
NCT02977156 Pexa-Vec (JX-594) + Ipilimumab Recruiting, phase 1, advanced solid tumours
Poliovirus
NCT04577807 PVSRIPO + Nivolumab Phase 2. Advanced, PD1 refractory melanoma
NCT03973879 PVSRIPO + Atezolizumab Withdrawn (resubmission planned), phase 1/2 glioma
VSV
NCT02923466 VSV-OFNb-NIS + Avelumab Active, not recruiting. Phase 1, refractory solid tumours
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combination with Pembrolizumab in recurrent GBM noted an
11.9% ORR with 2 ongoing durable responses in the 49 patients
recruited, median OS was 12.5 months (83). CG0070 is an
oADV armed with GM-CSF. A phase II study evaluating intra-
vesical CG0070 in combination with pembrolizumab in
immunotherapy-refractory non-muscle-invasive bladder cancer
(NMIBC) is ongoing (NCT04387461).
LOAd703 is a modified oADV armed with immune-
stimulatory transgenes TMZ-CD40L and 4-1BBL. A phase 1/2
trial is currently recruiting and will evaluate LOAd703 in
combination with standard of care chemotherapy (Gemcitabine/
nab-Paclitaxel) and Atezolizumab in PDAC (NCT02705196).
Pancreatic cancer is notoriously immune-excluded, however
combination treatment was shown to increase antigen-specific T
cells and reduce circulatingMDSCs, with a partial response in 6/10
subjects in an interim report (84). Finally, the modified oADV
TILT-123 encodes two immunostimulatory cytokines (IL2 and
TNFa) with promising pre-clinical activity in combination with
anti-PD-L1 therapy. A study combining TILT-123 with anti-PD-
L1 agent Avelumab is planned for 2021.
Other Locally-Delivered OV in Clinical
Development
Synergy has been demonstrated between oncolytic Coxsackie
viral strain CVA21 (Cavatek) and ICPI therapy and, as with
other OV, added toxicity in combination was minimal. Changes
within the TME were seen following CVA21 treatment, with
increased CD8 T cell infiltration and upregulation of PD-L1 and
other immune checkpoint receptors. The phase Ib MITCI trial
evaluated IT CVA21 therapy in combination with Ipilimumab in
patients with advanced melanoma. An ORR of 38% was observed
with no dose-limiting toxicity (85) (NCT02307149). Interim
results of the phase I CAPRA study of IT CVA21 and
Pembrolizumab therapy, also in advanced melanoma, showed
an ORR of 73% with regression of injected and non-injected
lesions (86), the study has completed although final results have
not yet been published. The phase I CANON trial of intra-vesical
CVA21 in NMIBC also showed transition of the TME to an
inflamed phenotype along with upregulation of immune
checkpoints such as PD-L1 and LAG-3 (87).
The modified vaccinia poxvirus JX-594 (Pexa-Vec) is also
under investigation in combination with ICPI therapy. A recent
phase Ib study in patients with renal cancer reported evidence of
treatment response in combination with Cemiplimab therapy.
The first phase of this trial involved IV oVV treatment, however
the second phase will evaluate localised IT therapy
(NCT03294083). A further study recruiting patients with
advanced solid tumours for combined IT JX-594 with
Ipilimumab is ongoing (NCT02977156).
Intratumoural injection of an oncolytic Vesicular Stomatitis
Virus (oVSV) construct VSV-hIFNbetasodium iodide symporter
is currently being tested in combination with avelumab in
advanced solid tumours (NCT02923466). The oncolytic
poliovirus, PVSRIPO, is also being tested in phase I trials in
combination with nivolumab in PD-1-refractory melanoma
(NCT0412759) and atezolizumab in glioma (NCT03973879).
All trials are currently recruiting.
RADIOTHERAPY
Evidence of involvement of the immune system in the anti-
tumour effect of radiotherapy has accumulated over many
decades. Radiotherapy-induced regression of tumour lesions
distant from the radiation field was first described almost 70
years ago and termed the “abscopal” effect (88). Over the years,
this rare phenomenon has been reported in several malignancies
(89, 90), while in mice, the role of T cells in controlling tumour
growth following radiotherapy has been described more recently
(91). These findings have spurred a growing field of research into
elucidating the determinants of radiation-induced immune
responses as well as the prospect of boosting the abscopal
effect with immunostimulatory agents, although whether, or
not, the abscopal designation truly applies when a systemic
immunotherapy is part of treatment remains a moot point.
Radiotherapy has traditionally been used to treat cancer by
utilizing the selective inability of cancer cells to repair DNA
damage. When radiotherapy is used as an immune adjuvant, the
aim is to transform the tumour into an individualized in situ
vaccine. This process requires increasing the antigenicity as well
as the adjuvanticity of the targeted tumour which is highly
dependent on firstly the mode of cell death that the irradiated
tumour cells undergo, secondly which molecular signalling
pathways are induced and thirdly which DAMPs are released
in the TME.
Radiation-Induced Tumour Antigenicity
Antigenicity is increased by inducing exposure and presentation
of mutation-associated tumour neoantigens, which are the key
targets for a T cell-mediated anti-tumour immune response, and
which correlate with response to ICPI (92). Radiotherapy has
been shown to promote an acute transcriptional programme
including genes associated with DNA damage and repair, many
of which are frequently mutated in tumours (93). Further,
radiotherapy increases the peptide pool through augmented
protein degradation and mTOR-regulated translation (27).
When combined with increased MHC class I expression, this
results in more antigenic peptides being presented for
recognition by the host immune cells and enhanced TCR
diversity (34). Indeed, Lhuillier and Lussier showed that
irradiation upregulates genes harboring immunogenic
mutations, resulting in selective elimination of irradiated
tumour cells by neoantigen-specific CD8 T cells in the 4T1
mouse breast cancer model and KP mouse sarcoma model
respectively (30, 94). In vivo focal irradiation of 4T1 tumours
was shown to broaden the TCR repertoire with expansion of T
cell clones driven by anti-CTLA-4 checkpoint inhibition (31).
Importantly, in a patient with metastatic NSCLC who
experienced a complete response to radiotherapy and
ipilimumab, Formenti et al. detected clonal expansion of an
immunogenic antigen derived from a gene upregulated by
radiation (29).
Radiation-Induced Tumour Adjuvanticity
DNA damage induced by ionizing radiation causes accumulation
of double-stranded DNA (dsDNA) in the cytosol, as well as
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micronuclei formation. This dsDNA is recognized by cyclic
GMP-AMP synthase (cGAS) (95) and subsequently activates
stimulator of interferon genes (STING), thus triggering the
transcription of Type I IFNs (96). A main role of IFNs in anti-
tumour immunity is to recruit DCs (97) and facilitate their
maturation and migration to tumour-draining lymph nodes
allowing for cross-priming of naïve T cells (98). The resulting
activation and bridging of innate and adaptive immune cell
responses ultimately promote proliferation and activation of
antigen-specific anti-tumour T cells.
ICD is defined by induction of certain DAMPs, all of which
are induced by radiotherapy (99) resulting in DC activation in a
dose and fractionation-dependent manner (100). The
importance of HMGB1 release from irradiated tumour cells for
effective radiation-induced tumour response was exemplified by
Apetoh and colleagues in two studies reporting dependency of
TLR-4 signalling for efficient antigen presentation by DCs and
tumour susceptibility to radiotherapy in mice and humans (26,
101). Further, increased translocation of calreticulin in human
breast, prostate and lung cancer cells following radiotherapy was
shown to increase their sensitivity to CD8 T cell lysis (43).
Conversely, radiotherapy was shown to downregulate CD47 in
head and neck tumours, counteracting its suppressive effect on
DC phagocytosis and resulting in pronounced radiation-induced
anti-tumour effect (102).
Radiotherapy and ICPI Combinations –
Pre-Clinical Studies
As evidence mounts of the ability of radiotherapy to alter the
immune composition of the TME, there are increasing efforts to
implement radiotherapy as an adjuvant to ICPI in patients that
are unresponsive to immunotherapy alone.
Radiotherapy (RT) has been shown to promote PD-1/PD-L1-
mediated immune resistance, setting the stage for potential
synergistic effects. PD-L1 surface expression was shown to be
elevated on tumour cells following radiotherapy, which has been
attributed to IFNg release from tumour-infiltrating lymphocytes
(TILs) (103). Tumour-infiltrating T cells have also exhibited
increased expression of PD-1 and 4-1BB following ex vivo
irradiation of colon- and gastric cancer tumour samples (104).
Indeed, PD-1/PD-L1 blockade administered concomitantly with
hypofractionated radiotherapy improved tumour control,
compared to radiotherapy or ICPI alone, and generated
sustained CD8 T cell responses and immunological memory
(103) while simultaneously reducing immune suppression by
myeloid-derived suppressor cells (MDSCs) (105).
Further, radiotherapy has been shown to potentiate the anti-
tumour effect of CTLA-4 blockade in a CD8 T cell-dependent
manner in the aggressive and poorly immunogenic breast cancer
model 4T1 (31, 33, 106, 107). In this model, radiotherapy was
shown to stabilize the immune synapse when CD8 T cells
engaged natural killer cell group 2D (NKG2D) with its ligand
retinoic acid inducible 1 (Rae-1) on target tumour cells (33).
Radiotherapy was also shown to promote T cell recruitment and
tumour infiltration by increasing production of the chemokine
CXCL16 (107). An increase in the TCR repertoire was
demonstrated following RT, with proliferation when RT was
combined with anti-CTLA-4 therapy. This was in contrast to
single-agent anti-CTLA-4 therapy, which led to fewer T cell
clones (31). Similarly, in a melanoma mouse model, CTLA-4
blockade cooperated with radiotherapy to increase the CD8
effector T cell to Treg ratio and diversify the T cell receptor
(TCR) repertoire resulting in therapeutic synergy. The anti-
tumour effect was further improved by addition of PD-L1
blockade to boost clonal expansion and offset T cell
exhaustion (28).
Recently, in the poorly immunogenic, ICPI-refractory KP
mouse sarcoma model, which has low mutational status, Lussier
et al. reported that low-dose irradiation of KP cells induced
immunogenic mutations generating neo-antigens sufficient to
convey T cell-mediated protection against the parental cell line
in vivo when combined with anti-CLTA-4 and anti-PD-1
treatment (94).
Clinical Translation
Robust pre-clinical evidence has meant that combinations of
radiotherapy and ICPI continues to be an area of ever-increasing
research interest. There are currently over 500 studies involving
clinical testing of these combinations, a number that has greatly
increased in recent years (Table 4).
Several retrospective studies have evaluated the potential
benefit of irradiation prior to checkpoint inhibition. Knispel
et al. recently reported results of a multi-centre retrospective
study of 835 patients with metastatic melanoma receiving anti-
CTLA-4 or anti-PD-1 therapy with or without previous
radiotherapy for unresectable metastases (108). No evidence of
benefit was seen with preceding radiation therapy. In contrast,
retrospective analysis of the KEYNOTE-001 phase I trial of
TABLE 4 | Summary of actively recruiting clinical trials evaluating radiotherapy in combination with immune checkpoint inhibition.
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NSCLC patients treated with Pembrolizumab showed an
improvement in PFS and OS in patients who had previously
been treated with radiotherapy (109). Neither study reported an
increased risk of adverse events with combination therapy.
A non-exhaustive selection of prospective clinical studies
evaluating RT/ICPI combinations is summarised in Table 5.
Formenti et al. investigated the mechanisms behind
response to combination anti-CTLA-4 and radiotherapy in
treatment-refractory NSCLC patients in a phase I/II study
(NCT02221739). Evidence of response was seen in 33% of
evaluable patients, with 2 complete responses. There was no
association seen between CD8 T cell infiltration or PD-L1
expression and response, however RT-induced IFNb secretion
and sustained TCR clonal expansion was associated with an
abscopal response (29). Conversely, a recent phase I study
evaluating RT in combination with anti-CTLA-4 in metastatic
melanoma showed CD8 infiltration to be significantly correlated
with PFS (NCT01557114) (110). McBride et al. also evaluated the
mechanics of the abscopal effect in a phase II study of Nivolumab
with or without SBRT in metastatic HNSCC. No statistically
significant differences were seen between treatment groups, with
no evidence of abscopal effects (NCT02684253) (111). The
combination of Pembrolizumab and RT in the definitive setting
in HNSCC is also being evaluated, a phase II study comparing
ICPI therapy with conventional chemoradiotherapy is currently
recruiting (NCT03383094).
Several key studies have evaluated combinations of RT and
checkpoint blockade in breast cancer, a site where RT presents a
cornerstone of treatment and where ICPI therapy has shown
limited efficacy to date. Phase III trials have supported the
approval of ICPI therapy in PD-L1-positive TNBC patients in
combination with chemotherapy, and subsequent trials of
combination ICPI/RT have yielded mixed results. Triple-negative
breast cancer is classically seen to be poorly immunogenic,
however has a high mutational burden with significantly higher
PD-L1 expression than other sub-types (112). A phase II study of
RT and Pembrolizumab in metastatic TNBC patients not selected
for PD-L1 expression showed that treatment was well tolerated
with some evidence of clinical activity in this poor-prognosis group
(17.6% ORR). The study reported 3 complete responses and
evidence of response outside the radiation field (NCT02730130)
(113). In contrast, Barroso-Sousa et al. reported negative results of
pembrolizumab and palliative radiotherapy in a small 8 patient
study of heavily pre-treated hormone receptor positive metastatic
breast cancer patients. No objective responses were seen, and the
median overall survival was 2.9 months (NCT03051672) (114).
Trials of additional combinations are planned, for example a phase
2 study combining Atezolizumab, radiotherapy and the TLR-7/8
agonist BDB001 is currently recruiting patients with PD-1/PD-L1-
refractory TNBC (NCT03915678). Three trials combining RT/
ICPI and Parp inhibitors are also planned in PD-L1-negative or
ICPI refractory metastatic TNBC (NCT04690855, NCT04683679).
As previously discussed, pancreatic cancer is notoriously
immune-excluded and ICPI-refractory. A phase I study
recently evaluated the safety of stereotactic body radiation
therapy (SBRT) and Durvalumab or Tremelimumab treatment.
No dose-limiting toxicities were seen with combination therapy,
and 2/39 patients had a partial response with an ORR of 5.1%
and PFS between 0.9 and 9 months depending on treatment
cohort (NCT02311361) (115).
The phase III PACIFIC trial showed that Durvalumab
therapy significantly improved survival compared to standard
of care concurrent chemo-radiotherapy in patients with locally
advanced stage III unresectable NSCLC (NCT02125461).
Antonia et al. reported a pronounced benefit in PFS with
Durvalumab treatment compared with placebo (16.8 months
vs 5.6 months respectively) (116), highlighting the potential for
upfront combination therapy in the definitive management of
TABLE 5 | A non-exhaustive representative summary of key clinical trials evaluating radiotherapy in combination with immune checkpoint inhibition.
NCT number Combination Study design Findings
NCT02125461 Sequential Durvalumab after concurrent
chemoradiotherapy (PACIFIC trial)
Phase 3, stage III unresectable NSCLC Median PFS 16.8 months (Durvalumab) vs 5.6 months
(placebo)
NCT02444741 50 Gy in 5 fractions SBRT + concurrent
Pembrolizumab
Phase 1/2, metastatic NSCLC Improved ORR, did not reach statistical significance
NCT02492568 24 Gy in 3 fractions + sequential
Pembrolizumab
Phase 2, metastatic NSCLC Improved ORR, did not reach statistical significance
NCT02904954 24 Gy in 3 fractions SBRT+ concurrent
Durvalumab prior to surgical resection
Phase 2, stage I, II, IIa NSCLC, neo-
adjuvant
Significantly higher major pathological response rate with
combination treatment (53.3%) vs single agent Durvalumab (6/
7%)
NCT02221739 30 Gy in 5 fractions (later 28.5 Gy in 3
fractions) RT + concurrent Ipilimumab
Phase 1/2, metastatic NSCLC. Evidence of response in 33% of evaluable patients.
NCT01557114 9, 15, 18 or 24 Gy in 3 fractions RT +
concurrent Ipilimumab
Phase 1, advanced melanoma 31% ORR, increased CD8+ T cells associated with improved
PFS
NCT02684253 27 Gy in 3 fractions + concurrent
Nivolumab
Phase 2, HNSCC No improvement in response and no evidence of abscopal
effect
NCT02730130 30 Gy in 5 fractions + concurrent
Pembrolizumab
Phase 2, TNBC ORR 17.6%, 3/17 CR
NCT03051672 20 Gy in 5 fractions + Pembrolizumab 2-7
days prior then every 21 days
Phase 2, metastatic hormone receptor
positive, HER-2 negative breast cancer
No objective responses, median OS 2.9 months
NCT02311361 8 Gy single fraction or 25 Gy in 5 fractions
+ Durvalumab/Tremelimumab/dual ICPI
Phase 1/2, PDAC ORR 5.1%, PFS between 0.9 and 9 months depending on
treatment cohort
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locally-advanced disease despite the mixed results discussed
above. These findings represent a pivotal milestone for the
clinical implementation of RT/ICPI combination therapy, and
the subsequent PACIFIC-4 trial has extended this combination
to early-stage NSCLC in stage I/II node negative disease.
Conversely, in locally-advanced HNSCC, the phase 3
JAVELIN-100 trial evaluating avelumab in combination with
standard-of-care chemoradiotherapy failed to meet its primary
endpoint of prolonged PFS. Of relevance, subgroup analysis
showed the only PFS benefit to be in patients with tumours
expressing high levels of PD-L1 (>25%) at baseline, and further
research is needed to evaluate the barriers to effective therapy in
“cold” tumours (117).
In the metastatic setting, the PEMBRO-RT (phase 2,
NCT02492568) (118) and MDACC (119) (phase 1/2,
NCT02444741) trials both noted a treatment benefit with
combination pembrolizumab/RT in NSCLC. This did not
reach statistical significance overall due to a small sample size,
however significance was noted in both studies in an exploratory
analysis of the sub-group of patients with tumours expressing
low levels of PD-L1 suggesting a potential benefit in “cold”
tumours. A recent pooled analysis of these two studies showed
a significant improvement in outcomes with the addition of RT
when compared to single-agent Pembrolizumab, with an OS of
19.2 months vs 8.7 months respectively (120).
A further treatment setting under evaluation is neo-adjuvant
treatment of patients with early-stage disease. A recent phase II
study of Durvalumab and SBRT therapy in NSCLC
(NCT02904954) showed a significant increase in major
pathological response rates with combination therapy when
compared to single agent Durvalumab (53.3% and 6.7%
respectively), validating the strategy for a larger trial (121).
This setting has also been evaluated in breast cancer. Pre-
operative RT and Pembrolizumab prior to standard-of-care in
patients with TNBC was shown to be well tolerated in published
interim results, with a pCR or 67%. Of note, baseline TIL count
of >10% was shown to corellate with complete response, but not
change in TIL over treatment (122). Finally, encouraging results
were seen in a recent phase Ib trial of neo-adjuvant SBRT and
anti-PD-1 therapy in HNSCC (NCT03247712), where the
combination was seen to be well tolerated with a high rate of
major pathological response (86%) (123).
OTHER LOCALISED THERAPIES
Other strategies aimed at TME manipulation towards a more
inflamed phenotype are also in clinical development. These
include locally-delivered immune-adjuvants, non-viral
oncolytics, and physical thermal therapies such as high
intensity focused ultrasound (HIFU). A non-exhaustive
selection of ongoing clinical studies are summarised in Table 6.
PV-10
Rose Bengal disodium is a small-molecule analogue of the
commonly-used conjunctival dye fluorescein and is under
clinical evaluation in its injectable form PV10 as a cancer
immunotherapy. Intralesional PV-10 has been shown
selectively to accumulate in lysosomes within tumour cells,
leading to immunogenic cell death, PAMP, DAMP and TAA
release, and an antigen-specific anti-cancer T cell response. Pre-
clinical synergy has been shown with IT PV-10 and anti-PD-L1
therapy, with the initiation of a CD8 T cell-dependent anti-
tumour immune response and depletion of Treg (124). A phase
Ib trial combining PV-10 with pembrolizumab met its primary
endpoint of safety in advanced melanoma and led to a complete
response (CR) in 9% with partial response in 57% - translational
correlative T cell data are awaited (125). Two expansion cohorts
are currently recruiting patients with checkpoint-inhibitor-
refractory melanoma (NCT02557321).
Toll-Like Receptor Agonists
Toll-like receptors (TLRs) are a family of PRRs that are most
commonly found on DCs and macrophages, but also on T cells
and tumour tissue. They play a key role in the innate and
adaptive immune response, recognising potentially harmful
TABLE 6 | A non-exhaustive summary of ongoing clinical trials evaluating other localised therapies in combination with immune checkpoint inhibition.
Agent and NCT number Combination Study design Status
Rose Bengal Disodium (PV-10)
NCT02557321 PV-10 + Pembrolizumab Phase 1, ICPI-refractory advanced melanoma Recruiting
TLR agonists
NCT03865082 Tilsotolimod (TLR-9 agonist) + Ipilimumab and Nivolumab Phase 2, solid tumours Recruiting
NCT04633278 CMP-001 (TLR-9 agonist) + Pembrolizumab Phase 2, HNSCC Recruiting
NCT03435640 NKTR-262 (TLR-7/8 agonist) + Nivolumab/pegylated-IL2 Phase 1/2, advanced solid tumours Active, not recruiting
NCT03301896 LHC-165 (TLR-7 agonist) + PDR001 (anti-PD1) Phase 1, advanced solid tumours Active, not recruiting
NCT03317158 BCG + Durvalumab + RT Phase 1/2, NMIBC Recruiting
STING agonists
NCT03010176 MK-1454 + Pembrolizumab Phase 1, advanced solid tumours Active, not recruiting
NCT04220866 MK-1454 + Pembrolizumab Phase 2, HNSCC Active, not recruiting
NCT03937141 ADU-S100 + Pembrolizumab Phase 2, HNSCC Active, not recruiting
Oncolytic Peptides
NCT04796194 LTX-315 + Pembrolizumab or Ipilimumab Phase 2, advanced solid tumours Recruiting
Thermal treatments
NCT03237572 HIFU + Pembrolizumab Phase 1, metastatic breast cancer Recruiting
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PAMPs and DAMPs including microbial nucleic acids and TAA
and triggering apoptosis and immune cell maturation
and recruitment.
Bacillus Calmette Guerin (BCG) is a live attenuated strain of
Mycobacterium Bovis, a potent agonist of TLR-2 and 4 that has
been routinely used in the treatment of bladder cancer for
decades. Schmidt et al. showed intra-tumoural injection of the
TLR-9 agonist lefitolimod led to remodelling of the TME to a
“hot” phenotype in mouse CRC models – with CD8 T cell influx,
an increase in the CD8:Treg ratio and a greater proportion of
M1-polarised macrophages (126). Enhanced therapeutic effect
was seen in combination with anti-PD-1 therapy (127).
Several clinical trials are ongoing evaluating TLR agonist/ICPI
combinations. The phase I/II ILLUMINATE-204 multi-centre
study evaluated intra-tumoural TLR-9 agonist (tilsotolimod)
therapy in combination with Ipilimumab in PD-1 refractory
metastatic melanoma (NCT02644967). Responses were seen in
local and distant lesions, with a 22.4% ORR (2 complete
responses) and a 21-month median OS. Tumour biopsies showed
evidence of an IFNa inflammatory gene signature and expansion of
CD8 T cell clones (128). The subsequent ILLUMINATE-301 trial
failed to achieve its primary end point, with no significant
improvement in ORR over Ipilimumab alone (NCT03445533)
(129). A further phase II study is ongoing recruiting patients with
microsatellite stable (MSS) colorectal cancer (CRC) for intra-
tumoural tilsotolimod in combination with ipilimumab
(ILLUMINATE-206, NCT03865082). Early results showed the
combination to be generally well tolerated with some evidence of
response in injected and non-injected lesions.
Milhem et al. (130) reported early results of an ongoing phase
1b trial of a further TLR-9 agonist (CMP-001) and
pembrolizumab in patients with PD-1-refractory melanoma. A
best ORR of 23.5% was seen with a median duration of response
of 19.9 months (NCT02680184). CMP-001 was also evaluated in
a recently completed phase I study in combination with
atezolizumab in PD-1-resistant NSCLC with or without
radiation therapy (NCT03438318). CMP-001 was delivered SC
(weeks 1 and 2) then IT (weeks 3-5) into visceral lesions.
Treatment had a tolerable safety profile and stable disease was
seen in a subset of patients. However, enrolment was stopped
after Stage 1 due to no objective responses CMP-001 is also being
evaluated in a Phase II trial in combination with Pembrolizumab
in HNSCC (NCT04633278). Preliminary results of a Phase Ib
study of TLR-7/8 agonist NKTR-262 in combination with
Nivolumab and pegylated IL2 in advanced solid tumours
(NCT03435640) showed enhanced immune infiltration and
early evidence of clinical activity (131).
Other ongoing clinical trials include the IT TLR-7 agonist
LHC165 in combination with anti-PD-1 in patients with
advanced solid tumours (NCT03301896), the TLR-8 agonist
motolimod in combination with anti-PD-1 agent nivolumab in
HNSCC (Phase 1, NCT03906526) and BCG in combination with
Durvalumab +/- RT in NMIBC (NCT03317158).
STING Agonists
The adaptor protein, STING, is a critical component of the
previously discussed cGAS/STING pathway and acts as a bridge
between innate and adaptive immunity. Cytosolic microbial or
tumour-derived DNA is sensed by the PRR, cGAS, which
undergoes conformational changes to catalyse ATP and GTP
into the cyclic di-nucleodide (CDN) cGAMP. STING is activated
on binding with cGAMP or other CDNs, leading to stimulation
of a type 1 IFN response, immune cell recruitment, promotion of
DC maturation and priming of antigen-specific immunity.
Most STING agonists in clinical development are human,
bacterially-derived or synthetic CDNs mimicking cGAMP. As
STING is located intracellularly on the ER, any agonist must
penetrate the cell membrane, leading to low bioavailability of
natural CDNs which are hydrophilic, electronegative and large in
size. Localised delivery via intratumoural injection therefore
provides a mechanism to enable therapeutic dosing within the
TME, although emerging novel agents such as non-nucleotide
small-molecule systemic STING agonists are in development for
intravenous or oral administration (132).
Preclinical evidence provides rationale for the combination of
STING agonism and ICPI therapy. In a poorly-immunogenic
mouse sarcoma model, STING deficiency was shown to limit
response to dual ICPI therapy highlighting an element of
dependence on STING-mediated immunity (22). Ager et al.
demonstrated that intratumoural injection of a STING agonist
in a poorly-immunogenic bi-flank model of TRAMP-C2 mouse
prostate cancer led to regression of injected but not non-injected
tumours. Addition of checkpoint therapy led to synergistic effects
in both injected and non-injected tumours, with an influx of CD8
effector cells, macrophage reprogramming and an increase in
CD8:Treg ratio (133).
Combination treatment with STING agonism and anti-PD-1
therapy was shown to enhance therapeutic effects in the T cell-
inflamedMOC1mouse model of HNSCC. In contrast, the non-T
cell-inflamed MOC2 model, used to represent “cold” tumours in
work by Moore et al, did not respond to either single agent
STING agonist or combination ICPI therapy. In these tumours,
STING agonism induced a type I IFN response but did not result
in CD8 TIL recruitment highlighting the inter-tumoural
complexity in TME modification (134). Enhanced efficacy was
seen with a combination of intraperitoneal STING agonist in
combination with conventional carboplatin chemotherapy and
anti-PD-1 checkpoint blockade in a model of high-grade serous
ovarian cancer, a notoriously “cold” tumour site. STING
agonism was shown significantly to enhance IFN production,
the infiltration of activated PD-1-expressing CD8 T cells and
MHCII expression in tumour-bearing mice (135).
A number of clinical trials evaluating STING agonism and ICPI
combinationsarecurrentlyongoing.Afirst inhumanphase I studyof
theSTINGagonistMK-1454 incombinationwithPembrolizumab in
advanced solid tumours or lymphoma (NCT03010176) reported an
encouraging safety profile and early evidence of efficacy (136). Phase
II studies evaluating STING agonistsMK-1454 (NCT04220866) and
ADU-S100 (NCT03937141) in combinationwithPembrolizumab in
HNSCC are currently active.
Melphalan
Melphalan is a nitrogen mustard alkylating chemotherapeutic
agent that has been widely used in cancer therapy. While
Appleton et al. Kickstarting Immunity in Cold Tumours
Frontiers in Immunology | www.frontiersin.org October 2021 | Volume 12 | Article 75443613
systemic therapy is known to cause lymphopaenia, localised
therapy has been shown to enhance immune cell infiltration
and antigen presentation through the initiation of apoptotic ICD,
while minimising systemic side effects. Ariyan et al. showed
synergy between local melphalan delivered via isolated limb
perfusion and systemic anti-CTLA-4 therapy, with remodelling
of the TME to an inflamed phenotype. This was translated into a
phase II clinical trial, where combination therapy was shown to
improve PFS with 62% complete responses and median PFS not
reached. However, this did not reach significance over either
treatment alone in the study of 26 patients (137).
Oncolytic Peptides
Designed to mimic natural antimicrobial peptides, oncolytic
peptides (OPs) are short polypeptides with a net positive
charge and a large proportion of hydrophobic amino acid
residues (138). This allows them selectively to enter through
negatively-charged phospholipid membranes, which are
preferential ly found in cancer cel ls due to higher
phosphatidylserine exposure (139). Oncolytic peptides LTX-
315/401 (140) and RT53 (141) have been shown to trigger ICD
and DAMP release (ATP, HMGB1 and Calreticulin), as well as
IFN I secretion, in melanoma and fibrosarcoma models; this was
associated with local immune infiltration and tumour regression.
In a mouse ovarian cancer model, local administration of the
gonadotropin-releasing hormone receptor (GNRHR)-targeted
peptide EP-100 was combined with anti-PD-L1-generating NK
cell, DC and CD8 T cell tumour infiltration. In a process
dependent on interleukin (IL)-33, T regs were simultaneously
depleted. In mouse models of fibrosarcoma (MCA205) and lung
carcinoma (TC-1), I.T. injections of LTX-315 (142)and LTX-401
(143) in combination with anti-PD-1 or anti-CTLA-4 promoted
immune-dependent control of injected and abscopal (non-
injected) tumour lesions.
LTX-315 is currently being explored in a phase I trial
including patients with transdermally-accessible tumours in
combination with pembrolizumab (NCT04796194).
Thermal and Ultrasound Based
Treatments
High-intensity focused ultrasound (HIFU) is a non-invasive
thermal modality, primarily used to treat solid tumours in
cancer patients who are poor candidates for surgery and
radiotherapy. HIFU was shown to induce ICD of human cancer
cells promoting generation of DAMPs as well as cytokines that
could polarize macrophages from a suppressive M2- to an anti-
tumour M1-phenotype (144, 145). In immunocompetent mice,
HIFU boosted DC infiltration in treated tumours and promoted
CD8 T cell cytotoxicity (146). The documented effects of HIFU on
DC recruitment, macrophage polarization and stromal
dissociation indicate that HIFU treatment could skew the TME
towards immune activation and possibly potentiate the effect of
ICPI or immune agonists to generate systemic and tumour-
specific immune responses. An ongoing phase 1 study is
currently evaluating HIFU in combination with Pembrolizumab
in metastatic breast cancer (NCT03237572).
Radiofrequency ablation (RFA) and microwave ablation
(MWA) uses needle-like electrode probes to deliver
radiofrequency and electromagnetic waves respectively,
generating oscillation and subsequent heating of the tumour
tissue. In two mouse models of breast (4T1) and colon (CT26)
cancer, MWA of primary tumours followed by combined anti-
PD-1 and anti-CTLA-4 treatment resulted in prolonged survival
compared with MWA or ICPIs alone. MWA + ICPI treatment
was also associated with increased frequencies of CD8 T cells in
treated tumours and peripheral blood as well as increased plasma
levels of IFNg (147). Neo-adjuvant RFA of NSCLC tumours
showed prominent CD8 and CD4 T cell infiltration in the
peripheral regions of RFA-treated tumours as well as increased
frequency of pro-inflammatory BDCA-3+ DCs in peripheral
blood suggesting systemic immune activation (148). A
retrospective study of colorectal cancer patients who had
received preoperative RFA to liver metastases showed
increased number of CD4 and CD8 TILs and increased PD-L1
expression in the resected primary tumours. An RFA-induced
transient abscopal immune activation and PD-L1 induction was
observed in a CT26 mouse tumour model with combined RFA
and anti-PD-1 antibody treatment showing synergistic T-cell
mediated systemic immunity (149).
Photothermal therapy (PTT) works by administering
optically-absorbent nanoparticles which, when activated by
near-infrared light, generates heat and localised thermal
damage (18). PTT, in combination with a TLR-7 agonist and
anti-CLTA-4 antibodies, induced abscopal effects in an
orthotopic 4T1 breast cancer model (150). A recent case report
describes a treatment-refractory HNSCC patient achieving a
complete and sustained tumour response to photodynamic
therapy (PDT) with anti-PD-1 antibody (151).
DISCUSSION AND FUTURE DIRECTIONS
Despite huge advances in recent years, ICPI therapy remains
largely ineffective in the treatment of immunologically cold
tumours. Although synergistic effects have been widely
demonstrated between localised immune-modulatory therapies
and ICPI, clinical response rates remain suboptimal. The
mechanisms of response and resistance are highly complex,
and it is likely that no single therapy will overcome tumour-
mediated immunosuppression across multiple tumour
histotypes. Multi-targeted combinations are likely to represent
the future of immunotherapeutic strategies, and an
overwhelming number of combinations are currently in
clinical development.
Localised therapy combinations have been shown to have
synergistic effects in some studies. RT has been shown to
synergise with OV and ICPI, for example a CTLA-4 armed
oNDV was shown to enhance sensitisation of melanoma cells to
radiation (152). Oba et al. also demonstrated efficacy of in situ
immune modulation using sequentially delivered local
therapies – RT, DC recruitment agent Fms-like tyrosine kinase
3 ligand (Flt3L) and TLR-3/CD40 stimulation - in overcoming
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checkpoint resistance in an immune-excluded mouse melanoma
model (153). A further recent clinical study provided evidence
that sequential oADV/HSV-TK, SBRT and anti-PD-1 was able to
restore ICPI sensitivity in NSCLC patients, with a 64.2% clinical
benefit rate (CBR) in patients that had received prior ICPI
therapy (154). This highlights the potential benefit of a multi-
targeted approach, even within localised therapies, and further
triple combinations are emerging, such as STING or TLR
agonists in combination with RT and ICPI.
Systemic targeted agents may also enhance treatment effects,
and one novel strategy is the use of agents that target cellular
DNA damage repair (DDR) pathways. An effective anti-cancer
immune response is dependent on the formation of tumour
neoantigens regardless of TME immunogenicity, a process that
may be a key limiting factor in ICPI efficacy in cold tumours, due
to a low mutational load. PARP inhibitors (PARPi) lead to un-
repaired DNA damage which triggers a cascade of immunogenic
events including enhanced PD-L1 expression on tumour cells,
immune cell infiltration and TAA formation (155), providing
rationale for combination treatment in cold tumours. PARPi was
seen to enhance OV-mediated oncolysis in a model of anaplastic
thyroid cancer (156). Treatment was also shown to enhance
radiosensitivity, with PARPi/RT leading to chemokine secretion,
immune infiltration and upregulation of PD-1/PD-L1 (157).
Clinical trials evaluating triple combination with PARPi/RT/
ICPI are ongoing (for example NCT04837209 and
NCT04926324). The ataxia telangiectasia and Rad3-related
(ATR) kinase is also integral to DDR pathways. Treatment
with an ATR inhibitor was shown to synergise with
radiotherapy and checkpoint inhibition in a pre-clinical model
of liver cancer (158).
Combinations involving co-stimulatory agonists such as 4-
1BB or CD40-L are also in clinical development. A recent study
in an orthotopic mouse model of pancreatic ductal
adenocarcinoma (PDA) revealed that an agonist targeting the
co-stimulatory receptor CD40 synergized with radiotherapy to
promote systemic tumour-targeted immune responses in
combination with dual ICB (159). In mouse models of
colorectal (MC38), melanoma (B16-OVA) and breast (4T1)
cancer, radiotherapy administered concomitantly with a 4-1BB
agonist resulted in local and abscopal anti-tumour immune
responses and prolonged survival, which was dependent on
CD8 T cells and conventional type I dendritic cells (cDC1a)
(104). Such combinations have also been investigated in the
context of oncolytic virotherapy, where the viral backbone
presents an opportunity for delivery of these agents limiting
toxicity. For example, Coffin et al. are currently testing an oHSV
armed with anti-CTLA-4, a 4-1BB agonist and CD40-L in early
phase clinical trials (68).
Novel checkpoints such as TIGIT, TIM-3, LAG3 (160) or
other inhibitory targets such as the CEACAM proteins (161) are
also under investigation, as are other triple combinations
involving alternate immunotherapies such as CAR-T cells
(162) or Bi-specific T cell engagers (BiTE) (163). As more is
known about the effects of T cell modulatory therapies such as
ICPI on the non T-cell constituents of the TME, the
understanding and effective application of future ICPI
combinations is likely to increase.
For example, the PD-1 pathway also regulates NK cells, B cells
and macrophages, and evidence for the impact of the diverse
cellular constituents of the TME on response to ICPI continues
to accumulate. Indeed, a study of ICPI therapy in melanoma
showed enrichment of B cell signatures in responding patients
(164), and conditional knockout of novel checkpoint TIM-3 on
DCs was shown to lead to inflammasome activation and anti-
tumour immunity, an effect that was not seen with TIM-3
deletion on CD4 or CD8 Tcells (165).
Selective deletion of PD-1 in myeloid cells has also recently
been shown to induce a more effective anti-cancer immune
response than ablation on T cells (166), and other innate
components such as Group 2 innate lymphoid cells (ILC2s)
are also emerging as critical elements of checkpoint-mediated
anti-cancer immunity (167). Understanding the complexities of
these relationships will be essential in deciphering mechanisms
of response, and identifying targets to overcome resistance.
As more complex combinations move into the spotlight, the
question of optimal dose delivery and scheduling becomes of
paramount importance both with regards to efficacy and toxicty.
There is a rationale for checkpoint blockade as a priming agent
before radiotherapy, and equally for OV administered prior to
ICPI to prime for an effective anti-cancer immune response.
Conversely, concurrent administration may enable maxiumum
synergy, and sequential ICPI delivered after localised therapy may
be the most effective way of sustaining immunity and overcoming
T cell exhaustion. This is currently under investigation, and
ongoing trials will begin to shed light on optimal scheduling. For
example, a study evaluating priming vs concurrent atezolizumab in
combination with conventional chemoradiotherapy in cervical
cancer has recently finished recruiting (NCT03738228). A study
combining an oADV with anti-PD-L1 agent Durvalumab is also
currently recruiting and will evaluate concomitant vs sequential
treatment (NCT03799744).
In the context of radiotherapy, the differential effects of dose-
fractionation on immunogenicity are also largely unknown.
Demaria et al. reported that RT doses above 12-18 Gy induced
the Trex1 exonuclease and attenuated any immunogenic effects,
while repeated lower doses led to IFN production, DC
recruitment and immune-cell priming (23), and fractionated
regimens have been preferred in some studies. For example,
Dewan et al. reported that fractionated but not single dose (20
Gy) radiotherapy induced an abscopal effect in a murine model
when combined with an anti-CTLA-4 antibody (168). In
comparison, some studies report hypofractionated doses are
more immunogenic, with a 15 Gy single fraction resulting in
greater tumour control and increased activation and infiltration
of antitumor T cells compared to 3 Gy x 5 in a B16/OVA murine
model of melanoma (169). Further questions include treatment
volume, especially when considering the immune effects of
lymph node irradiation, which has been shown to attenuate
adaptive anti-cancer immunity by altering CD8 T cell trafficking.
Further evaluation may have an impact on radiotherapy target
volumes of the future (170).
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For OV treatment, a key limitation to optimal delivery is that
many typically “cold” tumour sites such as brain, pancreatic and
ovarian, do not have easily accessible lesions for repesated
injection. Viral infectivity is highly heterogenous, and the
barrier of anti-viral immunity, either from prior infection,
vaccination or neutralizing antibodies (nAb) secondary to OV
treatment, also hinders viral replication and therefore efficacy
following systemic delivery. Novel methods of viral
encapsulation to overcome the barrier of anti-viral immunity
may provide a potential method of enhancing anti-tumour
effects, for example, Francini et al. published evidence of
ablation of nAb binding without viral inactivation using a new
class of coating polymers (171).
There is much still to learn in order to overcome the lack of
ICPI efficacy in cold tumours and to maximise the synergistic
benefit of localised therapy combinations. However, continued
research intended specifically to understand the biological
changes occurring in tumours following administration of
localised therapies is laying the groundwork for the design of
more effective strategies. Checkpoint inhibitors have been proven
to provide a widely-applicable method of immune rejuvenation,
and are likely to form an integral part of future strategies. With
the ability of localised therapies to manipulate the TME and
enhance tumour immunogenicity without excessive additive side
effects, they remain an attractive addition to the therapeutic
armoury, with the potential of rendering more patients
responsive to immune checkpoint blockade.
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